Thermo Fisher Scientific Inc. Siemens Healthcare GmbH and BD are Dominating the U.S Multiple Myeloma Diagnostic Market in 2019

U.S. Multiple Myeloma Diagnostic Market is expected to grow with the CAGR of 7.8% in the forecast period of 2019 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-multiple-myeloma-diagnostic-market

U.S multiple myeloma diagnostic market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.   

The major players dealing in multiple myeloma diagnostic market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. 

For instance:

  • In March 2016, Thermo Fisher Scientific Inc. acquired Affymetrix. This acquisition has helped the company in expanding the company's existing portfolio of antibodies and assays for flow cytometry and single-cell biology applications.

Thermo Fisher Scientific Inc. is the dominating player in U.S multiple myeloma diagnostic market. The other key players existing in the market includes NeoGenomics Laboratories, Inc., Helena Laboratories Corporation, Bracco Diagnostic Inc., Cytognos S.L., ZYTOVISION GmbH, Adaptive Biotechnologies, BioVendor, TriVitron Healthcare, Eurofins Scientific, Quest Diagnostic Incorporated, BD, Invivoscribe, Inc., BioFluidica, SkylineDx, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc. and Laboratory Corporation of America Holdings, GenPath.

U.S. Multiple Myeloma Diagnostic Market

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is headquartered in Massachusetts, the U.S was founded in the year 2006. The company focuses in manufacturing, distributing and services of medical devices and pharma services. The company operates its business through several business segments including laboratory products & services, life sciences solutions, analytical instruments, specialty diagnostics in which specialty diagnostics is the market focused segment. The product categories of the company include life sciences, industrial & applied sciences, clinical & diagnostics, lab solutions in which clinical & diagnostics is the market focused category.  

For instance,

  • In March 2016, Thermo Fisher Scientific Inc. acquired Affymetrix. This acquisition has helped the company in expanding the company's existing portfolio of antibodies and assays for flow cytometry and single-cell biology applications.

The company has wide presence across North America, South America, Europe, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such Thermo Fisher Scientific Malaysia Sdn. Bhd. (Peru), Laboratory Management Systems, Inc.(Delaware), Thermo Fisher Scientific (DE) Holding S.a.r.l (Luxembourg), Thermo Fisher Scientific Senior Financing LLC (Delaware), Thermo Fisher Scientific Operating Company LLC (Delaware) among others.

Siemens Healthcare GmbH

Siemens Healthcare GmbH is headquartered is in Erlangen, Germany. The company founded in the year 1896. The company focuses on providing supply services in power gelation, transmission as well as medical diagnosis. The company operates its business through three business segments including imaging, diagnostics and advanced therapies in which diagnostics is the market focused segment. The company has various product categories including medical imaging, laboratory diagnostics, point-of -care testing, digital health solutions, services & consulting, clinical specialties, accessories, OEM & electronics and healthcare IT in which laboratory diagnostics is the market focused category.

  • In October 2019, Siemens Healthcare GmbH signed an agreement for acquisition of ECG Management Consultants. The company has signed this agreement in order to implement the company’s strategies to attain accelerated growth in medical diagnostics field.

The company has presence across North America, Europe, Middle East and Africa, Asia-Pacific. The company also generates its revenue from the various subsidiary companies such asg Befund24 GmbH (Erlangen), FAST TRACK DIAGNOSTICS RESEARCH LIMITED (Dunblane/United Kingdom),  Siemens Healthcare Limited, Frimley (Surrey/United Kingdom), Minicare B.V. (Amsterdam/Netherlands) and Siemens Healthcare Diagnostics GmbH (Vienna/Austria) among others.

BD

BD is headquartered in New Jersey, the U.S founded in 1897. The company is focused on providing medical supplies, devices, and laboratory equipment's and high quality diagnostic product to their customers. The company operates its business through medical, life sciences, interventional business segments in which life sciences is the market focused segment. The product categories of the company include blood and urine specimen collection, diabetes, diagnostic system, infusion, infection prevention, others in which diagnostics systems is the market focused category.

  • In December 2019, BD wins PCRA’s social media campaign of the award. Further, this campaign will raise the awareness regarding importance of getting tested and audience engagement. This will help the company in raising their vale among the patients globally.

The company has presence in North America, Europe, Asia-Pacific, Middle East and Africa, South America. The company also generates its revenue from the various subsidiary companies such as CareFusion (U.S.), C.R. Bard (U.S.), Straub Medical AG (U.S.), FlowJo LLC (U.S.), Becton Dickinson U.K. Ltd (Europe) among others.